(Q38233004)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

main subject

patient

0 references

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Giuseppe Palasciano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Bhavna Rani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Francesco Dituri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Yuan Cao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

English

0 references

publication date

21 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1668-1676

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25053718%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Etiology-dependent molecular mechanisms in human hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

The microenvironment of the tumour-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

A new nomenclature for the laminins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Hepatic stellate cells stimulate HCC cell migration via laminin-5 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Cellular interaction of integrin alpha3beta1 with laminin 5 promotes gap junctional communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Dysregulation of apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Targeting the NF-κB pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

The roles of TGFβ in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

G1 cell-cycle control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

The snail superfamily of zinc-finger transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Angiogenesis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Connective tissue growth factor (CTGF) and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Establishment of human tumor xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Patient-derived tumor xenografts: transforming clinical samples into mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-307323